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1. Introduction 
The main problem with the common oral dosage forms is that they have to be swallowed along with water and 
many patients find it difficult to swallow tablets, especially in elderly and pediatrics, because of the physiological changes 
associated with these groups. Due to this dysphagic condition, they do not comply with prescription, which results in 
patient non-compliance. Thus FDTs are beneficial to patients who find it difficult to swallow tablets, moreover some of the 
drugs which are soluble in saliva are absorbed from the mouth, and pharynx and esophagus as the saliva passes down into 
stomach, which enhances bioavailability by avoiding first pass metabolism. [1-6]
 
Difficulty in swallowing (Dysphasia) is common among all age groups, especially in elderly, and is also seen in 
swallowing of conventional tablets and capsules. Geriatric and pediatric patients and travelling patients who may not have 
ready access to water are most in need of easy swallowing dosage forms. Another study shows that an estimated 50% of the 
population suffers from this problem. These studies show an urgent need for a new dosage form that can improve patient 
compliance. Solid dosage forms that can be dissolved or suspended with water in the mouth for easy swallowing are highly 
desirable for the pediatric and geriatric population, as well as other patients who prefer the convenience of readily 
administered dosage forms. In order to allow fast disintegrating tablets to dissolve in the mouth, they are made of either 
very porous or soft moulded matrices or compressed into tablets with very low compression force. Fast disintegrating drug 
delivery (FDDTs,) can be achieved by various conventional methods like direct compression, wet granulation, moulding, 
spray drying, freeze drying, and sublimation. The oral fast‐disintegrating tablets are also known as-fast dissolve, rapid 
dissolve, rapid melt and quick disintegrating tablet. However, the function and concept of all these dosage forms are similar. 
By definition, a solid dosage form that dissolves or disintegrates quickly in the oral cavity, resulting in solution or 
suspension without the need for the administration of water is known as an oral fast dispersing dosage form. Recently, the 
European Pharmacopeia adopted the term orodispersible tablet for a tablet that disperses or disintegrates in less than 3 
minutes in the mouth before swallowing. Such a tablet disintegrates into smaller granules or melts in the mouth from a hard 
solid to a gel-like structure, allowing easy swallowing by patients. 
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There are several synonyms in use of FDTs like orodisperse, orally disintegrating tablets, quick dissolving tablets, 
fast melt tablets, rapid disintegrating tablets. The tablets are disperse in oral cavity hence called orodisperse, dissolves in 
mouth within a matter of seconds hence called quick dissolving and rapid disintegrating tablets.   These tablets releases the 
medicament in the mouth for absorption through local oromucosal tissue and through pregastric (oral cavity, pharynx, and 
esophagus), gastric (stomach), and post gastric (small and large intestine) segments of gastro intestinal tract. [7-10]
 
 
2. Materials and Methods 
2.1 Manufacture of Ciprofloxacin tablets: [11-25] 
2.1.1 Direct compression technique: 
Ciprofloxacin tablets were manufactured for six batches F1 to F6 using different ratios of superdisintegrants 
mentioned in the Table keeping the total weight (500mg) of the tablet constant in all the formulations. 
Ciprofloxacin tablets were prepared by direct compression technique as per the formula given in the Table. The 
superdisintegrants such as croscarmellose sodium, crospovidone and sodium starch glycolate were used in different 
proportions. All the ingredients were passed through sieve #40 and were subjected for drying to remove moisture content at 
40 to 45
0
C. Weighed amount drug and excipients except magnesium stearate and talc were mixed properly by geometric 
addition method for 20 minutes manually.Talc and magnesium stearate were then passed through sieve #80, mixed and 
blended well with the initial mixture. The mixed blend of drug and the excipients was compressed  on Karnavati 10 station 
rotary punching machine using 8 mm diameter round  punches. 
Table 3: Formulation of Ciprofloxacin Fast Dissolving Tablets Prepared by Direct Compression Method (1 Tablet) 
Ingredients Formulation Code & Quantities (mgs) 
F1 F2 F3 F4 F5 F6 
Ciprofloxacin 250 250 250 250 250 250 
Sodium starch glycolate (%) 25 20 - - - - 
Crosscarmellose sodium (%) - -    25 20 - - 
Crospovidone (%) - - - - 25 20 
Lactose 90 95 90 95 90 95 
Mannitol 70 70 70 70 70 70 
Aerosil 30 30 30 30 30 30 
Magnesium stearate 15 15 15 15 15 15 
Talc  20 20 20 20 20 20 
Total weight  500 500 500 500 500 500 
2.2 Experimental Data: 
2.2.1 Preformulation Studies: 
The following Preformulation studies were performed for Ciprofloxacin and excipients; 
1. Determination of melting point of Ciprofloxacin  
2. Drug- excipients compatibility studies. 
Determination of melting point: 
Melting point was determined by taking small amount of Ciprofloxacin in a capillary tube closed at one end. The 
capillary tube was placed in an electrically operated melting point apparatus and the temperature at which the drug melts 
was recorded. This was performed thrice and average value was calculated. 
Drug-excipients compatibility studies: 
Excipients were integral components of almost all pharmaceutical dosage forms. The successful formulation of a 
stable and effective solid dosage forms depends on the selection of excipients, which are added to facilitate administration 
of the drug and protect it from degradation. 
2.2.2 FT-IR Studies: 
In the preparation of tablet formulations, drug and polymer may interact as they are in close contact with each 
other, which could lead to the instability of drug. Preformulation studies regarding the drug-polymer interaction are 
therefore very critical in selecting appropriate polymers. FT-IR spectroscopy was employed to ascertain the compatibility 
between Ciprofloxacin and selected polymers. The pure drug, drug-polymers combinations and formulations were 
subjected to FT-IR studies. Potassium bromide, pure drug, and the polymers were heated to 105
0
C for one hour to remove 
the moisture content if present in a hot air oven. Then in presence of IR lamp, potassium bromide was mixed with drug and 
/or polymer in 1:1 ratio. Grinding in smooth mortar can effect mixing. The mixtures were then placed in the sample holder 
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of the instrument and the spectra were taken. The spectra were run from 4000 cm-1 to1000 cm-1 wave number. FT-IR 
spectrum of Ciprofloxacin was compared with FT-IR spectrum of Ciprofloxacin with polymer. The pure drug and the drug 
with excipients were scanned separately. Disappearance of Ciprofloxacin peaks or shifting of peak in any of the spectra was 
studied. 
2.2.3 Preparation of Ciprofloxacin standard stock solution (100μg/ml) in Phosphate Buffer ph 6.8 solution: 
A standard stock solution of Ciprofloxacin was prepared by dissolving accurately weighed 10 mg of Ciprofloxacin 
in Phosphate Buffer ph 6.8 solution in a 100 ml volumetric flask and the volume was made up to 100 ml by using 
Phosphate Buffer ph 6.8 solution to obtain a stock solution of 100μg/ml.   
2.2.4 Calibration curve of Ciprofloxacin in Phosphate Buffer ph 6.8 solution: 
 An accurately weighed 10 mg of Ciprofloxacin was dissolved in 100 ml of Phosphate Buffer ph 6.8 to get a 
concentration of 100 μg/ml.  
From this stock solution, aliquots with suitable dilutions were made in order to get concentration in between the Beer’s 
range of 2-20 μg/ml. The dilutions of 2 μg/ml, 4μg/ml, 6μg/ml, 8μg/ml and 10μg/ml were prepared. The absorbance was 
measured at 276 nm using UV visible spectrophotometer. The standard curve was obtained by plotting absorbance V/s 
concentration in μg /ml.   
 
3. Results 
3.1 Evaluation of Tablets: [26-38] 
3.1.1 Pre-compression parameters:
 
Melting Point: 
The melting point of Ciprofloxacin was determined by capillary tube method and it was found to be 311
0
C -318
0
C.  
 
Figure 1: Standard Calibration Curve of Ciprofloxacin. 
3.1.2 Drug- excipients Compatibility Studies: 
  
Figure 2: IR spectra of Ciprofloxacin 
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Figure 3: IR spectra of Ciprofloxacin + Crospovidone 
 
 
Figure 4: IR spectra of Ciprofloxacin + Croscarmellose sodium 
                
Figure 5: IR spectra of Ciprofloxacin + Sodium Starch Glycolate 
3.1.3 Angle of repose (θ): 
Table shows the results obtained for angle of reposes of all the formulations. The values were found to be in the 
range of 26.55 to 29.63 All formulations showed the angle of repose within 30
0
. It indicates that all formulations showed 
good flow properties. 
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Table 4: Angle of Repose, Loose Bulk Density, Tapped Bulk Density, Carr’s Compressibility Index 
Formulation 
Code 
Angle of Repose(θ) 
(degree) 
Loose Bulk 
Density(gm/cm
3
) 
Tapped Bulk 
Density (gm/cm
3)
 
Compressibility 
(Index %) 
Hausner’s 
ratio 
F1 26.56 0.47 0.46 15.18 1.17 
F2 26.69 0.46 0.48 14.03 1.16 
F3 27.56 0.45 0.47 13.90 1.14 
F4 26.55 0.43 0.50 14.28 1.16 
F5 29.01 0.48 0.56 15.73 1.17 
F6 29.63 0.49 0.58 15.97 1.18 
 
3.1.4 Bulk density: 
Both loose bulk density LBD and tapped bulk density results are shown in table 4 the loose bulk density and 
tapped bulk density for all the formulations varied from 0.43gm/cm
3
 to 0.49gm/cm
3 
and 0.46gm/cm
3 
to 0.58gm/cm
3 
respectively. The values obtained lies within the acceptable range and not large differences found between loose bulk 
density and tapped density. This result helps in calculating the % compressibility of the powder. 
3.1.5 Percentage compressibility: 
The percent compressibility of powder mixture was determined by Carr’s compressibility index. The table Shows 
result obtained for percentage compressibility. The percent compressibility for all the nine formulations lies within the 
range of 13.90 to 15.97 %.  All formulations are showing good compressibility. 
3.1.6 Hausner’s ratio: 
Hausner ratio of the powder was determined from the loose bulk density and tapped bulk density. Hausner ratio of 
all the formulation lies within the acceptable range. The Hausner’s ratio of all the formulations is in the range of 1.14 to 
1.18. 
3.2 Post-compression parameters: 
All the formulations were subjected for Organoleptic, physical and chemical evaluations. Shape, thickness, 
hardness, friability, weight variation, in vitro disintegration time, wetting time, water absorption ratio, drug content, in vitro 
dissolution studies were carried out. All the formulations were passed the parameter. 
3.2.1 Shape and Color of Tablets: 
Randomly picked tablets from each formulation batch examined under lens for shape and in presence of light for 
color. The tablet shows round shape, white in color. All ingredients used were white in color. There was no change in color 
and odor of the tablets in all the formulations. It indicates that all the excipients used were compatible with the drug and did 
not cause any chemical reaction that affects the properties of formulation. 
3.2.2 Thickness Test: 
The thickness of the tablets was measured by using Vernier caliper by picking the tablets randomly. The mean 
values are shown in table. The values are almost uniform in all formulations. Thickness was found in the range from 
4.2±0.06 mm to 4.2±0.14mm respectively. Uniformity in the values indicates that formulations were compressed without 
sticking to the dies and punches. 
3.2.3 Hardness test: 
The results of hardness are given in table 5 Hardness test was performed by Monsanto hardness tester. Hardness 
was maintained to be within 3.1±0.10 kg/cm
2 
to 3.2±0.20kg/cm
2
. The lower standard deviation values indicated that the 
hardness of all the formulations were almost uniform and posses good mechanical strength with sufficient hardness. 
3.2.4 Friability: 
The results are tabulated in table was found well within the approved range (<1%) in all the formulation. Friability 
was in between 0.204% to 0.466%. Results revealed that the tablets possess good mechanical strength. 
3.2.5 Weight variation test: 
The percent weight variation for all the formulation is tabulated in Table. All the tablets passed weight variation 
test as the % variation was within the pharmacopoeia limit of ±10%. It was found to be from 500±1 mg to 501±2 mg. The 
weight of all the tablets was found to be uniform. This is due good flow property and compressibility of all the 
formulations. 
3.2.6 Drug content uniformity: 
The content uniformity was performed for all nine formulations and results are shown in table. Three trials from 
each formulation were analyzed spectrophotometrically. The mean value and standard deviation of all the formulations 
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were calculated. The drug content of the tablets was found between 95.96 % to 97.35 % of Ciprofloxacin. The results 
indicated that in all the formulations the drug content was uniform. 
3.2.7 Wetting time: 
Wetting is closely related to inner structure of tablets and the hydrophobicity of excipients. The record of the 
wetting time was shown in table 6. The wetting time in all the formulation was very fast. This may be due to ability of 
swelling and also capacity of absorption of water. Croscarmellose sodium, Crospovidone, Sodium starch glycolate absorbs 
water in all the formulations and shows fast wetting time. Apart from all the superdisintegrants formulations containing 
Crospovidone shows fast wetting time. 
Table 5:  Uniformity of Thickness, Hardness and Friability 
Formulation 
Code 
Uniformity of Thickness 
(n=3) (mm) 
Hardness (n=3) 
(Kg/cm
2
) 
Friability% 
(n=10) 
F1 4.2±0.06 3.1±0.10 0.306 
F2 4.2±0.08 3.2±0.13 0.466 
F3 4.2±0.14 3.2±0.12 0.256 
F4 4.2±0.12 3.2±0.16 0.305 
F5 4.2±0.06 3.2±0.20 0.204 
F6 4.2±0.07 3.2±0.09 0.265 
 
Table 6: Uniformity of Weight and Drug Content 
Formulation Code Uniformity of Weight  
(n=10) (mg) 
Drug Content 
(n=3) (%) 
F1 500±1 96.85 
F2 501±2 98.00 
F3 500±3 96.23 
F4 501±2 95.96 
F5 500±4 97.35 
F6 500±5 98.83 
 
Table 7: Wetting Time, Water Absorption Ratio 
Formulation 
Code 
Wetting Time (n=3) 
Mean ±SD 
Water Absorption Ratio 
(n=3) Mean ±SD 
F1 25±0.35 90.74±0.016 
F2 26±0.23 86.67±0.013 
F3 24±0.35 85.64±0.010 
F4 21±0.32 87.31±0.035 
F5 25±1.30 90.74±0.052 
F6 27±1.23 93.67±0.036 
 
Table 8: In vitro Disintegration Time, In vitro Dispersion Time 
Formulation 
Code 
In vitro Disintegration 
Time (Sec) 
In vitro Dispersion Time 
(Sec) 
F1 17±0.37 21±1.09 
F2 16±1.46 23±1.20 
F3 20±0.99                 20±.55 
F4 21±0.58 23±1.35 
F5 18±1.19 22±1.52 
F6 15±0.53 21±0.15 
 
3.2.8 In vitro dissolution studies: 
In vitro dissolution study was performed by using dissolution test apparatus (electro lab) at 50 rpm. Phosphate 
buffer pH 6.8 of 900 ml was used as dissolution medium which maintained at 37±0.5
0
C. Aliquot of dissolution medium (5 
ml) was withdrawn at specific time interval (3 min) and was filtered. The amount of drug dissolved was determined by UV 
spectrophotometer (Shimadzu 1800, Japan) by measuring the absorbance of the sample at 276 nm. Three trials for each 
batch were performed and average percentage drug release with standard deviation was calculated and recorded.    
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Table 9: In vitro Dissolution Profile of all the Formulations 
Formulation 
code 
After 3 min % 
Release 
After 6min % 
Release 
After 9 min % 
Release 
After 12 min % 
Release 
After 15 min % 
Release 
 0.00 0.00 0.00 0.00 0.00 
F1 21.68 44.56 52.63 76.86 84.47 
F2 19.93 27.49 43.65 67.23 79.44 
F3 23.68 32.63 39.58 56.82 78.31 
F4 29.78 43.38 51.25 62.93 74.11 
F5 16.62 29.28 56.90 76.63 88.10 
F6 23.72 47.63 57.51 77.69 89.68 
 
 
Fig. 6  In-vitro Drug release profile of batch F1 & F2 
 
Fig. 7 In-vitro Drug release profile of batch F3 & F4 
 
Fig. 8 In-vitro Drug release profile of batch F5 & F6 
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4. Conclusion 
 Preformulation studies of Ciprofloxacin were performed, the FT-IR analysis revealed that the superdisintegrants and 
excipients used were compatible with Ciprofloxacin 
 Fast dissolving tablets Ciprofloxacin can be prepared by direct compression technique using superdisintegrants, namely 
crospovidone, sodium starch glycolate and croscarmellose sodium. 
 Amongst all the formulations, formulation containing crospovidone as superdisintgrants is fulfilling all the parameters 
satisfactorily. It has shown excellent in vitro disintegration, in vitro dispersion time compared to other 
superdisintegrants. 
 Apart from all the formulations of F6 formulation showed maximum drug release (89.68%) at the end of 15 sec.  
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